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Platelets can be considered sentinels of vascular system due to their high number in
the circulation and to the range of functional immunoreceptors they express. Platelets
express a wide range of potential bacterial receptors, including complement receptors,
FcγRII, Toll-like receptors but also integrins conventionally described in the hemostatic
response, such as GPIIb–IIIa or GPIb. Bacteria bind these receptors either directly, or indi-
rectly via fibrinogen, fibronectin, the first complement C1q, the von Willebrand Factor,
etc. The fate of platelet-bound bacteria is questioned. Several studies reported the ability
of activated platelets to internalize bacteria such as Staphylococcus aureus or Porphy-
romonas gingivalis, though there is no clue on what happens thereafter. Are they sheltered
from the immune system in the cytoplasm of platelets or are they lysed? Indeed, while
the presence of phagolysosome has not been demonstrated in platelets, they contain
antimicrobial peptides that were shown to be efficient on S. aureus. Besides, the fact that
bacteria can bind to platelets via receptors involved in hemostasis suggests that they may
induce aggregation; this has indeed been described for Streptococcus sanguinis, S. epider-
midis, or C. pneumoniae. On the other hand, platelets are able to display an inflammatory
response to an infectious triggering. We, and others, have shown that platelet release
soluble immunomodulatory factors upon stimulation by bacterial components. Moreover,
interactions between bacteria and platelets are not limited to only these two partners.
Indeed, platelets are also essential for the formation of neutrophil extracellular traps by
neutrophils, resulting in bacterial clearance by trapping bacteria and concentrating antibac-
terial factors but in enhancing thrombosis. In conclusion, the platelet–bacteria interplay is a
complex game; its fine analysis is complicated by the fact that the inflammatory component
adds to the aggregation response.
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INTRODUCTION
The molecular make-up of platelets, which are specialized in repair
and in innate immunity (1–4), makes these “cells” unique blood
elements. The recognition of platelets as cells is still controversial,
primarily due to their lack of a nucleus. However, the multitude
of functions that have recently been attributed to them and that
are presented in this manuscript support our decision to con-
sider them as such throughout these studies. The platelet response,
Abbreviations: Bcl, B-cell lymphoma; C1q, first complement component;
CD40L, CD40Ligand; Clf, clumping factor; CTAP3, connective tissue activat-
ing protein-3; DIC, disseminated intravascular coagulation; E. coli, Escherichia
coli; Fas, apoptosis stimulating fragment; Fnbp, fibronectin-binding protein;
gC1q-R, gC1q receptor; Gsp, glycosylated streptococcal protein; hBD-1, human
beta-defensin-1; IE, infectious endocarditis; Ig, immunoglobulin; IL, inter-
leukin; Isd, iron-regulated surface determinant; ITAM, immunoreceptor tyrosine-
based activation motif; LPS, lipopolysaccharide; Mac-1, macrophage-1 antigen;
mRNA, messenger RNA; MSCRAMM, microbial surface components recogniz-
ing adhesive matrix molecules; NET, neutrophil extracellular trap; NO, nitric
oxide; NOS, nitric oxide synthase; OCS, open canalicular system; P. gingivalis,
which was once believed to only be involved in hemostasis, is
in fact extremely complex and probably adapts when required.
In this review, we will address the inflammatory potential of
platelets when confronted with pathogenic invasion, and more
specifically when it involves bacteria or viruses. We will focus
on their ability to directly trigger an immune response, rang-
ing from recognition of the pathogen to the orchestration of its
elimination.
Porphyromonas gingivalis; PAF, platelet-activating factor; PAFR, platelet-activating
factor receptor; PAR, protease-activated receptor; PF4, platelet factor-4; PMP,
platelet microparticles; PmP, platelet microbicidal proteins; PS, phosphatidylserines;
RANTES, regulated on activation, normal T cell expressed and secreted; ROS, reac-
tive oxygen species; S. aureus, Staphylococcus aureus; S. epidermidis, Staphylococcus
epidermidis; S. gordonii, Streptococcus gordonii; S. pyogenes, Streptococcus pyogenes;
S. sanguinis, Streptococcus sanguinis; sCD40L, soluble CD40L; Sdr, serine–aspartate
dipeptide repeat; SEB, staphylococcal enterotoxin B; SrpA, serine-rich protein A;
SSL, staphylococcal superantigen-like; TLR, Toll-like receptor; TNF, tumor necro-
sis factor; Tx, thromboxane; vWF, von Willebrand factor; ∆Ψm, mitochondrial
membrane potential.
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PLATELETS AND BACTERIAL INFECTIONS
PLATELETS AT THE INTERFACE BETWEEN BACTERIAL INFECTION AND
THROMBOSIS
Example of infectious endocarditis
Cardiovascular diseases, although varied, may have infectious ori-
gins, as was described by Beynon et al. concerning infectious
endocarditis (IE) (5). The main bacterial agents involved in IE
are Staphylococcus aureus, Streptococcus sanguinis, and Streptococ-
cus gordonii (S. gordonii). According to epidemiological studies,
bacteremia that leads to the development of this disease may be
the consequence of a local intervention, but there may be a more
distant origin such as the recurrent administration of a drug or a
surgical dental procedure.
By creating an inflammatory environment, bacteria adhere to
the valvular endothelium and increase its permeability, thus lead-
ing to the exposure of subendothelial tissue factors. The circulating
platelets then adhere to the subendothelium, and their hemostatic
activation causes the formation of a thrombus, which can then
lead to arterial ischemia, and even pulmonary embolism (6). IE is
therefore a disease that links inflammation and hemostasis, though
it was long accepted that platelet activation occurred indirectly.
In IE, analysis of a newly formed thrombus in the myocardium
showed the presence of bacteria inside the platelet clot (7). The
first hypotheses suggested that this bacterial presence stabilized
the platelet clot due to the activity of bacterial enzymes specialized
in coagulation [coagulase for S. aureus (8) or the “clumping fac-
tor” (Clf) for the other staphylococci (9)], although without direct
participation in platelet activation.
In sepsis, microthrombi form in the blood capillaries (10). As
with IE, this phenomenon was attributed to the inflammatory
environment that promoted platelet aggregation. The study by
Osterud et al. also supports this hypothesis, since the authors
show that in severe sepsis, the circulating monocytes show an
increased expression of tissue factors, which thus support platelet
aggregation (11).
Beginning in 2005, publications describing the role of platelets
in immunity put prior observations related to the direct inter-
action of platelets and bacteria back in the spotlight (12). They
then suggested that the binding of bacteria to platelets should
even be considered a factor in the immune response. Today, the
growing number of studies based on the inflammatory potential of
platelets show that these cells express a variety of receptors, soluble
molecules, and signaling factors (both hemostatic and inflamma-
tory), enabling them to secure their position as direct effectors of
antibacterial defense. This function is presented in the following
sections.
Inflammatory and thrombotic role of platelet microparticles
Platelets also form the link between thrombosis and inflammation
through the production of microparticles. Platelet microparticles
(PMP) are phospholipid vesicles (100–1000 nm) that are released
after budding from the platelet plasma membrane. As a result,
PMP express the same antigens as their parent cells, i.e., GPIIb–
IIIa, GPIb, CD31, CD61, and CD62P. This distinguishes them from
microparticles derived from other cell types (red blood cells, leuko-
cytes, monocytes, endothelial cells). PMP thus make up between
70 and 90% of the circulating vesicles. PMP differ from exosomes
by their size, but also due to the fact that they are not derived from
exocytosis of multivesicular bodies (13).
Platelet microparticles are released by the activated platelets
in apoptosis or senescence. A central factor in the induction of
this event is the detachment of the actin cytoskeleton from the
plasma membrane, which occurs primarily through the increase
in intracellular calcium concentration. The calcium then interacts
directly with the proteins involved in proteolysis of the cytoskele-
ton, such as calpain (14, 15). The formation of PMP may also
occur independent of calcium, in which case it involves the C5B–
9 complement factor and activation of protein kinases, such as
calmodulin (16).
Bacterial infection also appears to be a source of PMP forma-
tion. This has already been well described during the involvement
of platelet Toll-like receptor (TLR) 4 (17–19) but also in response
to the Shiga toxin (20).
Platelet microparticle formation results in an asymmetrical dis-
tribution of the membrane phospholipids. The circulating PMP
thus express phosphatidylserines (PS), which are highly pro-
coagulant phospholipids, on their surface (21). PMP also express
tissue factor, the major initiator of the coagulation cascade (22–
24). PMP have also been described as a surface that enables the
in vitro generation of plasmin; this ability was not found in
microparticles isolated from endothelial cells (25).
Platelet microparticle are also capable of issuing immunomod-
ulatory factors, such as regulated on activation, normal T cell
expressed and secreted (RANTES) (26), interleukin (IL)-1β (18),
and CD40Ligand (CD40L) (27), and can also modulate the activa-
tion of inflammatory cells such as neutrophils (28, 29). PMP even
seem to be able to exert their pro-inflammatory activity outside of
the blood compartment (30). The pro-inflammatory function of
PMP is referred to in greater detail throughout this manuscript.
Finally, the proportion of PMP in the circulation is increased
in some illnesses, such as cardiovascular disease (22), sepsis (31),
or HIV infection (32), which suggests they may be involved in the
pathophysiology of these diseases.
MECHANISMS OF INTERACTION BETWEEN PLATELETS AND BACTERIA
Three mechanisms of interactions between bacteria and platelets
have been described to date: (1) the indirect binding of bacteria
to a plasma protein, which itself is a ligand of a platelet recep-
tor; (2) the direct binding of bacteria to platelet receptors; and
(3) the binding of secreted bacterial products, particularly tox-
ins, to platelets. The mechanisms of interaction are made more
complex by the diversity of platelet receptors involved in bacterial
recognition.
Role of glycoprotein IIb–IIIa
In addition to ensuring their usual function in hemostasis, the
platelet glycoproteins play a role in the adhesion to bacteria. The
first platelet receptor identified as such was GPIIb–IIIa. This inte-
grin, specifically from the megakaryocyte cell line, is the receptor
for fibrinogen. Its involvement results in adhesion and platelet
aggregation (33, 34).
Staphylococci express surface receptors that are specific for
fibrinogen and fibronectin (Figure 1). These are surface pro-
teins characterized by regions rich with serine–aspartate repeats,
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FIGURE 1 | Involvement of GPIIb–IIIa in the adhesion of bacteria to
platelets. Schematic representation of different bacterial components, which
bind to the platelet GPIIb–IIIa either indirectly via fibrinogen or fibronectin (left
side of the diagram) or directly (right side of the diagram). Clf, clumping factor;
Fnbp, fibronectin-binding protein; SdrG, serine–aspartate repeat protein; Isd,
iron-regulated surface determinant; Pad, platelet adherence protein.
belonging to the microbial surface components recognizing
adhesive matrix molecules (MSCRAMM) family (35). These mol-
ecules enable bacteria to adhere to tissues, a critical step in the
establishment of infection. Some of the most common exam-
ples of MSCRAMM are found in S. aureus: ClfA (36), ClfB (37),
fibronectin-binding protein (Fnbp) A, and FnbpB (38). Staphylo-
coccus lugdunensis binds to fibrinogen via its Fbl protein, which is
58% identical to ClfA (39).
The binding of Staphylococcus epidermidis was long unknown,
even though it had already been shown that trypsin treatment in
a culture of S. epidermidis prevented its adhesion to platelets (40),
suggesting the involvement of a membrane factor. In 2009, Bren-
nan et al. showed that serine–aspartate dipeptide repeat (Sdr) G
proteins expressed on the surface of S. epidermidis are necessary
for the adhesion of bacteria to platelets via fibrinogen (41).
Even though these various MSCRAM are highly similar pro-
teins, they bind to fibrinogen via different binding sites. ClfA and
Fbl, as well as FnbpA and B, bind to the C-terminal region of the
fibrinogen γ-chain. ClfB has its binding site on the C-terminal
region of the fibrinogen α-chain, and SdrG on the β-chain. Other
types of bacteria can also bind to fibrinogen, particularly Strepto-
coccus pyogenes (S. pyogenes) via the M1 protein, and Streptococcus
mitis via the enzyme, lysine (42).
More recently, bacteria have been described that also express
surface proteins, enabling them to bind directly to GPIIb–IIIa,
independent of fibrinogen (Figure 1). Such is the case for SdrG
from S. epidermidis, which in addition to binding fibrinogen, can
also directly target the platelet glycoprotein (41).
In vivo, S. aureus must find a source of iron that will enable
it to grow and ensure its pathogenicity. To do so, it expresses
iron-regulated surface determinant (Isd) proteins that are capa-
ble of binding the heme from hemoglobin and internalizing
it. Yet, it has been shown that IsdB in particular can bind to
GPIIb–IIIa in the absence of plasma protein. This adhesion
is inhibited in the presence of platelets that have been pre-
incubated with anti-GPIIb–IIIa antibodies, and in bacterial strains
mutated for IsdB, confirming the specificity of the binding (43).
S. gordonii also expresses a platelet adherence factor that has
been recently described, platelet adherence protein A (PadA),
and for which no other known function has been found to
date (44).
The binding site(s) involved with GPIIb–IIIa have still not been
mapped; however the use of peptides mimicking the arginine–
glycine–aspartic acid chain, the ligand usually described for the
involvement of the glycoprotein in hemostatic conditions, pre-
vents the direct attachment of bacteria on platelets (42). This
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observation suggests that the bond may be the same type as with
fibrinogen.
Role of glycoprotein Ibα
GPIbα is a membrane glycoprotein and is also only found in the
megakaryocyte cell line. It belongs to the family of leucine-rich
repeat proteins. It is capable of binding several ligands and is
essential in primary hemostasis through its high affinity with von
Willebrand factor (vWF). It is important to remember that GPIbα
is found as a complex with GPIb β, GPIX, and GPV at a ratio of
2:2:2:1 (34).
It has been shown that several species of Streptococcus are able to
bind directly to GPIbα (Figure 2). This interaction involves a fam-
ily of highly glycosylated, serine-rich bacterial proteins. This family
includes serine-rich protein A (SrpA) from S. sanguinis (45), as
well as glycosylated streptococcal protein B (GspB) and hemagglu-
tinin salivary antigen (Hsa) from S. gordonii (46). These bacterial
proteins, which are highly similar, bind to the sialic acids of the
host’s receptors. The staphylococcal accessory regulator (Sar) P
protein expressed by S. aureus also allows adhesion to platelets
(47). The fact that SrpA and GspB are molecularly very close has
led to the hypothesis that the SrpA–platelet bond could involve
GPIbα.
Bacterial proteins are capable of binding to vWF, although they
are fewer than those binding to fibrinogen (Figure 2). It has been
shown that protein A from S. aureus is capable of binding to vWF
(48–50), which in turn interacts with GPIb β. The same applies
to a surface protein of Helicobacter pylori, though it has still not
been completely characterized. This study on the platelet–bacteria
interaction involving vWF shows that if vWF is already bound to
bacteria, it does not require shear forces to adhere to GPIb β (51).
Complement receptors
The literature describes platelets’ ability to interact with the com-
plement system. This is mainly observed in activated platelets,
thereby allowing their clearance, but also in platelets in a patho-
logical environment (Figure 3). For example, C5b–9 is found at
detectable levels on the surface of platelets in 14% of patients with
coronary artery disease. From a molecular perspective, comple-
ment is capable of activating platelets by inducing the expression
of pro-coagulant factors, such as prothrombinase complex, on the
surface of the cells (52).
Complement proteins also interact with bacteria both through
the conventional pathway and the alternative pathway (53, 54).
S. sanguinis for example induces platelet aggregation involving
complement (55). ClfA and ClfB from S. aureus also induce
aggregation that is dependent on complement (56).
Platelets express gC1q-R, the receptor of C1q, and could thus
serve as a receptor for bacteria coated with these complement fac-
tors. Following platelet activation, the expression of gC1q-R on the
FIGURE 2 | Involvement of GPIb in the adhesion of bacteria to platelets.
Schematic representation of different bacterial components, which bind to
the platelet GPIb either indirectly via the von Willebrand Factor (vWF, left side
of the diagram) or directly (right side of the diagram). Gsp, glycosylated
streptococcal protein; Srp, serine-rich protein; Hsa, sialic acid-binding
hemagglutinin.
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FIGURE 3 | Complement factors in bacterial binding to platelets. Bacteria
coated with C1q factor recognized by the gC1q receptor (gC1q-R) on platelet
membrane, which is overexpressed upon platelet activation. Moreover, the
CD62P marker, expressed by activated platelets, is able to recognize the C3b
factor. Besides, alpha-granules contain a C1q inhibitor, which limits the
interaction between C1q and gC1q-R.
platelet surface is significantly increased (57). Platelet activation
also leads to the increase of CD62P at the membrane, which has
been reported to bind C3b, another complement protein (58).
This interaction of platelets with complement can be bivalent.
On the one hand, platelets can assist in the destruction of bacte-
ria by increasing the activity of complement, but since they bind
complement proteins, they themselves can become the target of
complement’s lytic activity. This is notably what occurs in the case
of thrombocytopenic purpura (52). Platelets however possess a
C1 inhibitor in their α-granule, which, during platelet stimulation,
would enable complement activation to be modulated (59).
This concept of platelet–bacteria binding by complement mol-
ecules involves a mechanism that is more immunologic than
hemostatic, which therefore highlights the dual function of
platelets.
FcγRIIa receptor
The expression of this immune receptor, which recognizes the
Fc domain of immunoglobulin (Ig)G, is typically described for
phagocytes, such as neutrophils and monocytes. FcγRIIa enables
the binding and internalization of immune complexes involving
IgG, whether soluble or cellular. This mechanism is regulated by
the fact that complexed IgG have a strong affinity for the receptor,
while it is very weak for monomeric IgG (60).
Blood platelets also express FcγRIIa (61), and it is the only
type of Fcγ receptor that has been described on platelets to date.
One of the first functions associated with platelet FcγRIIa involves
its role in the pathophysiology of autoimmune disorders. In
cases of heparin-induced thrombocytopenia, Reilly et al. described
autoantibodies that recognized the platelet factor-4 (PF4)–heparin
complexes binding to the platelet FcγRIIa. The involvement of the
receptor then results in strong hemostatic activation, followed by
clearance of the activated platelets (62).
Immunoglobulin G bound to bacteria are also capable of being
taken by this platelet receptor. As with leukocytes, the immune
complexes that bind FcγRIIa can even be internalized by the
platelets (63).
The stimulation of other platelet receptors by bacteria very
often requires the simultaneous involvement of FcγRIIa in order
to obtain an effective platelet response. This suggests a link between
the involvement of FcγRIIa and the mechanisms of aggregation.
On average, platelets express approximately 5,000 copies
of FcγRIIa (42). Considering the large number of circulating
platelets, these are thus the richest reservoir of FcγRIIa, and indeed,
they are therefore a significant cell in the antibacterial platelet
response.
BACTERIAL TOXINS
Bacteria may also secrete toxins that are capable of activating
platelets. Porphyromonas gingivalis secretes a family of cysteine
proteases called gingipains. These toxins are capable of recogniz-
ing the platelet protease-activated receptor (PAR) 1 and cleave
it in a manner similar to that of thrombin, thereby making it
functional (64).
Alpha-toxin, expressed by strains of S. aureus, binds to the lipid
bilayer membrane of platelets to form a pore, followed by a flow of
calcium, similar to that induced by calcium ionophore (65). Other
toxins capable of forming pores on the platelet surface have also
been described. These include streptolysin O from S. pyogenes (66)
and pneumolysin from Streptococcus pneumoniae (67).
Staphylococcus aureus and S. pyogenes produce a superfam-
ily of toxins called staphylococcal superantigen-like (SSL) toxins,
which have a known superantigenic effect. Of them, SSL5 inter-
acts directly with GPIbα via the sialyl lactosamine residues that
terminate its glycan chain. This toxin also has a direct affinity for
GPIV (42).
EFFECTS OF BACTERIA ON PLATELET FUNCTION
Most studies focusing on the adhesion of bacteria to platelets show
that it is a result of aggregation. The scope of this manuscript does
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not include coagulation; only the characteristics of aggregation
and inflammation after bacterial contact are addressed.
INTERNALIZATION OF BACTERIA
During systemic bacterial infection, pathogens are generally cap-
tured by phagocytes. When Clawson studied the interaction
between platelets and bacteria in the 1970s, he occasionally
observed the internalization of S. aureus in some platelets (12,
68, 69). Youssefian et al. (70) confirmed these observations, which
concerned the internalization of S. aureus in particular. Electron
microscopy photographs show the internalization of S. aureus
in platelets, within vacuoles that are independent of the open
canalicular system (OCS), suggesting active internalization.
Platelets have a better capacity for internalization when they are
activated by a conventional agonist [adenosine diphosphate (ADP)
or thrombin], which underscores a common mechanism between
activation and internalization. Immunohistochemical labeling of
vacuoles containing S. aureus shows the presence of CD62P and
GPIIb–IIIa, but not GPIb, the phenotype that corresponds to
that of an activated platelet membrane. The vacuole may there-
fore be formed through invagination of the plasma membrane
(endocytosis) after activation.
A Japanese team confirmed the internalization of S. aureus in
platelets but only after activation of the latter by ADP. The same
study shows that P. gingivalis can also be internalized in platelets.
There appears however to be a different mechanism of internal-
ization at work in both bacteria. Indeed, P. gingivalis is capable of
inducing it alone, without the addition of another platelet agonist,
as the platelet aggregates are adequate for internalization of the
bacteria (71).
Staphylococcus aureus and P. gingivalis share a common element
with regard to internalization, as both types of bacteria are inter-
nalized in the vacuoles independent of the OCS (71). Although the
final result is the same, it is thus possible that Gram-positive and
Gram-negative bacteria may have different internalization mech-
anisms, suggesting that one of them has an additional molecule
promoting its internalization. It must be emphasized that on the
pictures from the study by Li et al., the presence of some P. gin-
givalis cells at the OCS may be explained by passive trapping of
bacteria during platelet aggregation (71).
Platelet FcγRII may also initiate the internalization of IgG–
pathogen complexes (63). One study indeed shows that platelets
are capable, after involvement of FcγRII, of internalizing poly-
styrene beads (0.5–1.5µm diameter) covered with IgG. This inter-
nalization is inhibited by cytochalasin D, suggesting the need to
remodel platelet actin for bacteria to be internalized (72).
There remains a question as to the outcome of the internalized
bacteria. White et al. reviewed arguments favoring the inability
of platelets to degrade/kill bacteria. Their main argument is the
absence of phagolysosomes in platelets (73). The internalization
of bacteria in platelets would enable them to escape the immune
system. Platelets could however use another pathway for destroy-
ing bacteria. Indeed, the endosome containing the pathogens has
the ability to merge with the alpha-granules containing many bac-
tericidal molecules (70). Finally, it is possible for Escherichia coli
(E. coli) to be destroyed by platelets via internalization by FcγRII,
provided that the bacteria have first been opsonized by IgG (72).
The fate of the bacteria internalized in the platelets thus remains
a subject of discussion, being either a means of defending the host
or an escape mechanism for the bacteria. Without progressing
to internalization however, adhesion of the bacteria or bacterial
products on the platelet surface is sufficient for inducing a defense
response from the platelets. The main reactions are described in
the following section.
PLATELET ACTIVATION BY BACTERIA
Effect on aggregation
Since bacterial binding to platelets includes receptors that are
also involved in hemostasis, some data show aggregation to be
dependent on bacteria. Bacteria that indirectly use GPIIb–IIIa (via
fibrinogen or fibronectin) bring about aggregation similar to that
observed with other fibrinogen-coated surfaces (42). However,
when there is direct adhesion between the bacteria and GPIIb–
IIIa, a different mechanism is used, and aggregation induction
is often controversial in the literature. S. gordonii, for example,
which binds directly to GPIIb–IIIa through its PadA protein, does
not induce aggregation (44), potentially due to a weaker affinity
for the receptor.
Bacteria that bind to GPIb via vWF can (contrary to soluble
or immobilized vWF) cause aggregation in the absence of shear
force. This is the case for S. sanguinis and S. gordonii, which bind
to platelets through their SrpA and GspB proteins, respectively.
Deletion of these two proteins completely eliminates this aggrega-
tion (42). These bacterial components are capable of substituting
for the shear forces, particularly by themselves ensuring platelet
rolling.
For other bacteria, S. pyogenes and S. aureus in particular, shear
forces are not necessary to induce the thrombus formation, but
the observed aggregation may involve other platelet proteins. The
hypothesis issued by Cox et al. is that the binding of bacteria to
GPIb might bring them close to functional platelet receptors such
as FcγRIIa or GPIIb–IIIa (42).
After stimulation by S. sanguinis, which involves GPIb, the
platelets release the contents of their dense granules that con-
tain vasoactive substances, including the adenosine nucleotides,
adenosine triphosphate (ATP) and ADP. Once released, ATP is
taken by the ecto-ATPases present on the surface of S. sanguinis
and hydrolyzed to ADP. The newly formed ADP, as well as that
released previously, will bind to their platelet receptor. The P2Y
pathway is therefore involved (42).
The use of aspirin during the adhesion of S. sanguinis to
platelets totally inhibits aggregation, also suggesting the role of
cyclooxygenase and the production of thromboxane (Tx)A2. The
platelets exposed to S. sanguinis produce TxA2, and the TPα recep-
tor then amplifies platelet activation by binding the newly released
TxA2.
Platelet activation induced by S. sanguinis may also involve the
MAP kinase pathways. McNicol et al. recently showed that MAP
kinases Erk2 and p38 underwent the triphasic stages of phospho-
rylation/dephosphorylation observed in other phosphoproteins.
Aspirin has no effect on phosphorylation and dephosphorylation
of Erk2 but is able to inhibit its rephosphorylation stage (74).
There is little data available concerning platelet signaling related
to the adhesion of S. aureus. Cox et al. showed that during the
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interaction of S. aureus with platelets, the induced aggregation is
dependent on the cyclooxygenase and Tx pathways (75). This study
focused mainly on the mechanisms of interaction, and therefore
further details on the intracellular mechanisms were not provided.
Several studies on platelet aggregation after bacterial adhesion
have also highlighted the need for FcγRIIa involvement if there
is to be an effective response (42). However, FcγRIIa functioning
could differ from that which is usually described, since, although
the observed aggregation requires FcγRIIa, IgG does not seem to
be essential (76). The colocalization of FcγRIIa with GPIbα during
bacterial stimulation might be the first step in signal transduction
(76, 77).
One of the most accepted hypotheses concerning the alterna-
tive role of FcγRIIa is based on platelet remodeling, since the GPIb
sequence that binds to FcγRIIa (R542G543R544) is the same that
binds to actin during platelet activation (77).
A similar type of study was conducted on FcγRIIa and GPIIb–
IIIa. Newman et al. showed that Src residue from GPIIb–IIIa,
capable of ensuring a role of tyrosine kinase, phosphorylates the
immunoreceptor tyrosine-based activation motif (ITAM) residue
of FcγRIIa and thus amplifies the platelet activation signals (78).
Phosphorylation of the ITAM motif may take place within 30 s
following contact, which shows that secondary signaling pathways
can be established very quickly.
Aggregation induced by bacteria is different from that observed
with the conventional ADP, ATP, and thrombin platelet agonists. It
is “binary” aggregation, meaning that aggregation is not observed
below a certain bacterial density, and aggregation is already at a
maximum when above that density (79).
The lag time required before the appearance of aggregation is
another parameter that differs according to whether the platelet
stimulation is bacterial or not. This lag time is generally longer with
bacterial stimulation than with hemostatic activation. Although
about 10 s are needed with a hemostatic agonist, some bacteria can
have a very quick lag time of 90–120 s, while others may need more
than 20 min before inducing platelet aggregation. Increased bacte-
rial density can decrease this time to a limited extent (79). Several
hypotheses have been proposed to explain the lag time variations
according to the bacteria: (1) the time required for platelets to bind
bacteria, particularly if it done indirectly; and (2) activation of the
receptor, which may not be as strong.
Bacteria-induced platelet aggregation nevertheless remains
controversial, and several studies show that bacterial stimulation
may not result in aggregation but a more targeted inflammatory
response [chemokines release, leukocyte activation, neutrophil
extracellular trap (NET) formation]. Based on current knowledge,
particularly on platelet TLR, other platelet responses to bacteria,
in addition to aggregation, may include the release of adapted
molecules.
Effect on the release of immunomodulatory factors
Platelets possess many bioactive molecules in their alpha-granules,
including cytokines/chemokines, which are released during their
activation and enable them to act during the immune response
(80, 81). The Canadian team that partners with our laboratory
and studies intraplatelet signaling after S. sanguinis stimulation
also performed a study on the secretion of platelet cytokines. Four
strains of S. sanguinis and one of S. gordonii were used for the
study.
The observation of aggregation and phosphorylation of signal-
ing molecules such as PCg2 and Erk confirms the pro-thrombotic
role of streptococci and also shows the release of RANTES, PF4,
soluble (s)CD40L, and platelet-derived growth factor (PDGF-AB).
CD62P is only released in the presence of one strain of S. sanguinis
(82). Another study had also shown that platelets were capable of
releasing soluble CD40L (sCD40L) and RANTES after stimulation
with IgG-bead complexes, with the absence of aggregation and a
very weak expression of CD62P (72).
Epinephrine, known to stimulate fibrinogen binding and
aggregation (83), causes the opposite effect on the release of
platelet cytokines. The mechanism of inhibition used is unknown
but could be linked to the activation of type 3 nitric oxide
synthase (NOS) after involvement of the β2 adrenoreceptors;
the resultant generation of nitric oxide (NO) and cGMP has
already been described in platelet activation inhibition (82). This
clearly demonstrates that platelet aggregation and exocytosis of
immunomodulating molecules are two independent functions.
One other platelet cytokine that is important in the antibacte-
rial response is PF4. In heparin-induced thrombopenia syndrome
(HIT syndrome), PF4 links to heparin through its positive charge,
and together they form a neoantigen that is recognized by IgG.
Likewise, soluble PF4 can bind to bacteria and thus form a new
recognition site for IgG and the effector immune cells (84). This is
particularly seen in Gram-negative bacteria, since PF4 presents an
affinity for bisphosphorylated lipid A of lipopolysaccharide (LPS)
bacteria. The newly formed complex is taken up the phagocytic
cells. Platelet PF4 might thus facilitate the clearance of certain
bacteria.
Finally, CD40L is the lead immunoregulatory molecule of
platelets. It has been found that over 95% of plasma sCD40L
originate from platelets (85). By comprising the main source of
this molecule, platelets become an indisputable immunoregula-
tory factor; they participate both in the activation of the effector
cells of innate immunity and that of adaptive immunity, since
CD40L is involved in immunological synapses, as well as in class
switching of B lymphocytes.
Following platelet activation, CD40L is first exposed to the
membrane in trimeric form (the biologically most active form)
and is then cleaved by proteolytic activity. Matrix metalloprotease
(MMP)-9 is currently thought to be the most likely candidate. It
should also be pointed out that the soluble form of platelet CD40L
may also have an autocrine effect due to the presence of CD40 on
the platelet surface (4, 86).
The involvement of CD40L in the full range of platelet func-
tions is substantiated throughout this manuscript. This molecule
is particularly implicated in the platelet response to bacteria, since
the involvement of platelet TLR-2 (87–91) and TLR-4 (87, 88, 90–
99) by means of their bacterial ligands, can specifically modulate
the release of sCD40L. As with leukocytes, the following triad is
thus observed: bacterial stimulation–platelet–detected release of
immunoregulatory molecules. Hence, the role of platelet sCD40L
in the pathophysiology of sepsis is an expanding field of study.
The platelet immunoregulatory molecules presented above are
of great interest in the context of the immune system activation,
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leading to bacterial elimination. The growing number of studies
on the interaction of bacteria and platelets shows that platelets can
also directly influence the elimination of microorganisms through
the release of bactericidal molecules.
Release of antibacterial platelet molecules
Kraemer et al. recently showed that platelets incubated with S.
aureus limit the growth of this microorganism (100). The small-
est platelet concentration for obtaining a bacteriostatic effect may
even be possible to determine, though this would vary depending
on the bacterial species. A 2013 study conducted on 17 volun-
teers was able to determine a critical platelet concentration for
pathogens from the human oral cavity: E. faecalis (resistant or
non-resistant to vancomycin), C. albicans, S. agalactiae, S. oralis,
and P. aeruginosa (101). It should be noted that the growth of P.
aeruginosa was not inhibited by platelet-rich plasma (PRP).
Despite these very recent studies, the first demonstration of
the antibacterial role of platelets occurred very long ago. As Yea-
man recounts in his literature review on the subject, Fodor already
reported in 1887, the bactericidal effect of heated sera (102). The
thermostable molecule involved was then identified and named
β-lysine. Its platelet origin is based on the fact that it is released in
coagulated plasma and is not found in the other blood cells.
Yeaman et al. were particularly interested in this platelet func-
tion and established terminology that classified these antimicro-
bial platelet molecules as platelet microbicidal proteins (PmP)
(102), also known as thrombocidins. PmP, of which there are two
(PmP1 and PmP2), are released under the induction of thrombin
or bacteria, and differ from classically described defensins by their
molecular mass, their sequence, and the chaining of lysine and
arginine residues, which gives them a cationic charge. To become
functional, these molecules must be cleaved by thrombin; the two
sub-units then act in an autonomous but complementary manner
by alternating the permeability of the bacterial wall (102).
The platelet signaling pathways that lead to the release of PmP
depend primarily on the ATP/ADP pair and the P2 receptors.
The signal is amplified through the release of ADP, and autocrine
activation of the platelets is produced, which can even extend to
neighboring platelets (103).
The PMP family was enlarged through the integration of
kinocidins, which includes the platelet cytokines that have a direct
bactericidal effect (104). They are divided into two subgroups
according to the nomenclature of the cytokines. Les α-kinocidins
include the CXC-cytokines [PF4, platelet basic protein (PBP),
connective tissue activating peptide (CTAP3), and neutrophil acti-
vating peptide (NAP2)], while the β-kinocidins are the CC-type
(RANTES). These molecules even have a synergistic effect among
themselves. For example, CTAP3 does not have an effect on the
viability of E. coli, but the presence of PF4 potentiates its activity
and thereby reduces the bacterial density by 2 logs. This result is
not obtained for PF4 alone (105). Structural biochemical analyses
identified the 60–74 structural domain in PF4 as being responsible
for the bactericidal activity (106).
Kinocidins are integrated in the mechanisms of innate immu-
nity, to the degree that they conserve their primary role, which is
the chemoattraction of leukocytes, enabling cooperation between
platelet and leukocyte factors in bacterial clearance (107, 108).
In addition, Kraemer et al. showed the presence of human β-
defensins 1 (hBD-1) in megakaryocytes and platelets at the level
messenger RNA (mRNA) and peptides (100). Platelet hBD-1 is
thus released in response to the alpha-toxin of S. aureus; it is
not released however in response to thrombin, thrombin receptor
activating peptide, or platelet-activating factor (PAF), suggesting
that hBD-1 release is independent of degranulation. hBD-1 may
therefore not be found in the alpha-granules, especially since the
authors did not observe colocalization of the markers of these
granules and of hBD-1 (100).
While Kraemer et al. were unable to observe the expression
of mRNA coding for hBD-2 and -3 in the platelets, other studies
have demonstrated their presence through ELISA, Western Blot,
and immunohistochemistry, as well as their microbicidal activity
(109, 110). As a result, it appears that platelets are involved in
the infectious immune response, both directly through the release
of antimicrobial factors, and indirectly through the release of
cytokines, enabling them to modulate the cell-mediated immune
response.
PLATELETS–BACTERIA: FOCUS ON STAPHYLOCOCCUS
AUREUS INFECTION
There are many studies on the interaction of platelets with Strep-
tococcus, particularly oral streptococci, while comparatively few
concern S. aureus. In 2005, a prospective study was conducted in
39 medical centers throughout 16 countries that included 1779
patients with IE. The final analysis showed that S. aureus was
the most common pathogen implicated, with 31.6% of cases ver-
sus 18% of Streptococcus viridans (111). Invasive infections by
methicillin-resistant S. aureus generally tend to spread in health
care centers and result in a high level of mortality (112). It is
therefore of interest to consider the role of S. aureus on platelets.
Most of the studies focus on molecules involved on both sides
during the adhesion of S. aureus to platelets (Figure 4). We first
looked at the interactions between the molecules present in the
membrane of S. aureus and platelets.
Protein A, which is a surface protein of S. aureus, can be identi-
fied by anti-S. aureus antibodies. The immune complexes formed
can attach to the FcγRII of the platelets, resulting in serotonin
release and platelet aggregation. This reaction is dependent on the
stimulation time and the quantity of immune complexes formed.
The activation was found to be optimal at 5 min, and from two
bacteria per platelet (75). In a more recent study, protein A was
found to be incapable of inducing aggregation by itself, but it was
able to maintain it (113).
Protein A from S. aureus can also attach to vWF, which binds
to GPIbα. The use of an antibody to block vWF partially inhibits
the platelet activation by S. aureus (79) providing evidence of the
involvement of several adhesion pathways.
Clumping factor A from S. aureus is also involved in its attach-
ment to platelets via fibrinogen (114). An alternative receptor
exists however, since S. aureus adheres to platelets through the
intermediary of fibrinogen/fibronectin, which does not necessarily
involve GPIIb–IIIa (115). This could be shown by the persistence of
aggregation, even if the two fibrinogen-binding sites on GPIIb–IIIa
are blocked beforehand. It is not impossible for bacteria to trans-
form fibrinogen so that it can be recognized by another receptor.
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FIGURE 4 | Interconnections between S. aureus and platelets.
S. aureus can induce platelet activation by several ways, e.g., through
toxin release or by using membrane protein that bind platelet receptors
either directly or indirectly. However, some bacterial factors induce the
inhibition of platelet function (gray frame on the right side of the
diagram). TLR, Toll-like receptor; Clf, clumping factor; FcγR, Fcγ
receptor; EAP, extracellular adherence protein; Isd, iron-regulated
surface determinant; Sdr, serine–aspartate repeat protein; Efb,
extracellular fibrinogen-binding protein; PAFR, platelet-activating factor
receptor.
This might thus be a method for the bacteria to increase their
pathogenicity.
FcγRII and GPIIb–IIIa both have a functional role in the adhe-
sion of S. aureus. The interconnection between these two receptors
explains why the aggregation induced by S. aureus is dependent on
FcγRII. This hypothesis also reflects the fact that the involvement
of FcγRII alone is not sufficient for inducing aggregation, since its
presence is meant to optimize the functionality of GPIIb–IIIa (79).
The identification of genetic mutations of S. aureus and the
expression of candidate proteins in L. lactis (non-aggregative bac-
teria) showed that ClfB and the SdrE protein are also involved in
platelet aggregation. The results also confirm the involvement of
ClfA, which is moreover the first factor, before ClfB, that leads to
aggregation, since it is the protein inducing the shortest lag time.
Aggregation induced by both these factors can be inhibited by
GPIIb–IIIa antagonists, aspirin, or prostaglandin E1 (75). Aggre-
gation is also seen with filtered platelets, suggesting a direct link
between S. aureus and platelets, independent of fibrinogen. Dif-
ferent results have been observed for the SdrE protein. In order
to attach to platelets, the bacterial protein requires the presence
of a plasma protein other than fibrinogen, which has yet to be
identified.
An important element to take into consideration is that S.
aureus does not express the same factors depending on its stage
of growth, which could be a bias in in vitro studies. ClfA is
the dominant pro-aggregant protein in the stationary phase of
growth, whereas in the exponential phase, FnBP expression dom-
inates (79). As a result of these indications, it becomes difficult,
for example, to evaluate the results of Fitzgerald, which confirm
his modeling of the interaction between FnBP and platelets on
bacteria in the stationary phase (116).
The complement system is important in platelet aggregation
induced by S. aureus. It is capable of substituting for ClfA. In this
instance, the lag time will be longer (between 8 and 20 min), but
simultaneous involvement of the Fcγ receptor remains necessary
(56).
The Staphylococcus protein, IsdB, could promote the adhesion
and internalization of bacteria within platelets in the presence of
fibronectin (117). In addition, this protein, unlike the IsdA and
IsdH proteins, might induce platelet aggregation (117).
Studies on the interaction between platelets and S. aureus began
in the 1970s and still continue today. The extracellular adherence
protein, EAP, in the form of an oligomer, can bind directly to the
glycosaminoglycans of platelets (118). This leads to the stimulation
of thiol isomerase in the platelet and resultant platelet activation,
ranging from stabilization of the fibrinogen binding, to the mem-
brane expression of platelet activation molecules, such as CD62P,
CD63, and CD40L.
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In addition to having to integrate the alternative role of hemo-
stasis receptors when confronted with S. aureus, there are also
newly described platelet receptors that increase the range of func-
tions. This particularly applies to TLR-2, which, by responding to
the peptidoglycan of S. aureus, results in platelet activation after
30 min in association with a process of apoptosis characterized by
depolarization of the mitochondrial membrane, exposure of PS to
the plasma membrane, and caspase 3 activation.
In addition to the membrane components and the bacterial
wall, S. aureus toxins can also modulate the platelet response
(Figure 4). It has been shown in vitro that the alpha-toxin can
interact with the platelet membrane and induce the production of
microbicidal proteins and lysis of bacteria (102). This toxin might
also be capable of generating dose-dependent platelet aggregation
(119). It can also lead to the de novo synthesis in the platelet of
B-cell lymphoma-3 (Bcl3) (119), a protein involved in the with-
drawal of the platelet plug. This exotoxin is also the source of the
formation of many platelet–neutrophil complexes via CD62P, an
activation marker expressed on the platelet surface. Formation of
the complexes increases the activation of neutrophils, which can be
measured through the increase of CD11b. These aggregates could
thus participate in the destruction of alveolar capillaries and be
the cause of S. aureus hemorrhagic pneumonia (120).
Staphylococcus aureus releases staphylocoagulase and vWF-
binding protein. Both of these molecules bind to prothrombin and
form the enzymatic complex known as staphylothrombin (121).
Staphylothrombin has no direct action on platelet activation, but
by transforming fibrinogen to fibrin, it plays a role in stabiliza-
tion of the aggregation, as well as in the initiation of secondary
activation.
It has been noted, however, that several S. aureus molecules
seem to actually inhibit the hemostatic function of platelets. In
this respect, staphylococcal enterotoxin B (SEB) has been observed
to cause platelet overactivation of protein kinase C (PKC). This
enzyme, essential for platelet response, is therefore no longer found
in physiological conditions and therefore cannot ensure its func-
tion. This explains why platelets incubated with SEB are incapable
of ensuring correct aggregation in response to thrombin (122).
Lipoteichoic acid uses the PAF receptor to increase the level of
cAMP within platelets. This latter then increases its phosphory-
lation activity on vasodilator-stimulated phosphoprotein (VASP)
and inhibits aggregation and thrombus formation (123). The anti-
thrombotic role of S. aureus can also be attributed to the extra-
cellular fibrinogen-binding protein (Efb). In vitro, this protein has
been described as adhering to platelets (on a non-characterized
receptor or on fibrinogen). Once attached, it recruits fibrinogen
but in a non-conventional form that is rather inclined to inhibit
platelet activation. The inhibitory action of this molecule was con-
firmed in vivo, in which it is able to prevent thrombosis following
treatment with platelet agonists (124).
Finally, staphylokinase also exerts inhibitory activity on the
platelets although indirectly. This enzyme degrades plasmin and
fibrinogen, thereby preventing aggregation (125). Several groups
are also studying the interaction of S. aureus and platelets under
conditions similar to those seen in vivo, particularly with regard
to preservation of the necessary shear forces. Mice infected by S.
aureus develop thrombi through a ClfA-dependent mechanism
(126). The use of a molecule occupying the binding site of ClfA on
fibrinogen completely prevents aggregation, which demonstrates
the predominance of ClfA, despite the multitude of other factors
present in the microenvironment.
Dogs with S. aureus infection quickly develop sepsis, accompa-
nied by platelet dysfunction (reduction in the capacity of growth
in response to a PAR-4 agonist). This latter result suggests that
beyond their role in IE due to S. aureus, platelets participate in the
pathophysiology of S. aureus-induced sepsis (127).
In addition, a duality can be seen in the effect of S. aureus
bacteria on platelets, indicating the complexity of the interaction.
All of the studies are based on whether the bacteria have pro-
aggregant or non-aggregant abilities. There is no data however
on the release of platelet cytokines, which is nevertheless a very
important component of bacterial infection.
ROLE OF PLATELETS IN THE PATHOPHYSIOLOGY OF SEPSIS
SEPSIS AND COAGULOPATHY
Data from the early 2000s show that between 30 and 50% of
patients with severe sepsis have disseminated intravascular coagu-
lation (DIC), resulting in organ hypoxia (128). During the inflam-
matory response, the neutrophils release tissue factors that trigger
the coagulation cascade, leading to platelet activation. IL-1 and
IL-6 are also strong inductors of coagulation (129, 130). This
phenomenon is amplified by deregulation of the anticoagulant
balance. Patients with sepsis have a strong release of PAI-1, a nat-
ural plasmin inhibitor. There is also a reduction in protein C,
the active form of which is an inhibitor of coagulation factors Va
and VIIIa (10, 129–133). In addition, these natural anticoagulants
have their role in thrombin generation, with anti-inflammatory
properties influencing nuclear factor κB (NFκB) (134).
Reactive oxygen species (ROS) released in massive quantities
during the acute phase of sepsis are also responsible for coag-
ulopathies. In mice with induced sepsis that are knocked-out for
NOS (the enzyme that produces ROS), vasoconstriction is reduced
compared to wild mice. By favoring vasoconstriction, ROS partic-
ipates in circulatory alteration in the blood capillaries. ROS also
have a direct effect on the hemostatic activation of platelets (132).
The fourth element favoring excessive coagulation is the
increase of adhesion factors. In endotoxemia models, the expres-
sion of adhesion molecules is increased in both the platelet and
endothelial membranes. The adhesion of platelets to the endothe-
lium promotes mutual activation and an accumulation of platelets,
resulting in vessel occlusion (118, 123). Furthermore, in endotox-
emia induced in a mouse model, it was seen that overexpression
of the endothelial PAI-1 molecule in the lungs limits the in situ
recruitment of regulatory T lymphocytes but promotes that of
neutrophils (135).
Sepsis-related coagulation disorders have highlighted the role
of platelets in the pathophysiology of sepsis, particularly through
their hemostatic function. However, it is now clear that platelets
also possess an inflammatory function that may enable them to
directly participate in the amplification of inflammation associ-
ated with the early phases of sepsis. In addition to their sensitivity
to thrombin, adhesion molecules, and cytokines/chemokines, the
hypothesis of their direct involvement in sepsis is also supported
by the TLR expression on their surface and the broad range of
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inflammatory molecules that they can release during bacterial
stimulation.
SEPSIS AND INFLAMMATORY PLATELET MOLECULES
The first elements supporting the participation of platelets in
sepsis-associated inflammation come from studies showing that
the level of circulating sCD40L is greater in patients with
sepsis than in individual controls (age- and gender-matched)
but independent of the severity of the sepsis (136–141). This
sCD40L released during sepsis comes from the platelets, since
mice that have undergone platelet depletion do not present this
increased plasma level (142). One recent study suggests that
matrix metalloproteinase-9, which is also increased during sepsis,
might be the source of platelet CD40L cleavage (143). This mole-
cule has important inflammatory properties affecting many cells,
both immune and non-immune, and may significantly amplify
inflammation (144, 145).
In sepsis, sCD40L participates in the recruitment of neu-
trophils. CD40L gene-deficient C57BL/6 mice that had sepsis
induced through cecal ligation puncture do not show neu-
trophil activation, edema formation, or neutrophil infiltration
in the lungs, and they maintain their alveolar microarchitec-
ture (142, 146).
Soluble CD40L may enable the expression of the macrophage-1
antigen (Mac-1) adhesion protein by neutrophils, promoting their
recruitment at the mucosa. The mechanism of action of sCD40L
may involve macrophage inflammatory protein 2 (MIP-2) and its
receptor, CXCR2. This is supported by the fact that in vitro recom-
binant sCD40L does not increase the expression of Mac-1 on the
neutrophils in culture (142).
Platelet-activating factor is a molecule synthesized by various
cells and that possesses a cytokine function. Its receptor, platelet-
activating factor receptor (PAFR), is attached to G proteins and
is expressed by the cells that participate in immune defense and
coagulation, including platelets. Platelet PAFR activation results
in the release of inflammatory factors, degranulation, and the
initiation of coagulation cascades. In physiological conditions,
signaling associated with PAFR is finely regulated in order to
avoid an excessive thrombo-inflammatory response. During sep-
sis however, this regulatory balance is disrupted, and PAF is then
involved in the activation of neutrophils, monocytes, platelets, and
in the formation of leukocyte–endothelium, leukocyte–platelet,
and platelet–endothelium complexes (147).
A recent study suggested an association between the duration
of storage of apheresis platelets before transfusion and the occur-
rence of complications in patients from a trauma center. This study
was conducted on 381 patients who had been admitted to a trauma
center and received apheresis platelet concentrates that had been
stored for 3 days or less, 4 days, or 5 days. The results show that
the transfusion of platelets stored for over 3 days may increase the
risk of complications for the patient, sepsis in particular (148).
It was shown that during the storage of platelet concentrates,
the platelets are activated, and the platelet inflammatory factors,
including sCD40L, are released and then accumulate (149–152).
This suggests that the inflammatory molecules that accumulate
during the storage of platelet concentrates could promote the onset
of sepsis.
It has also recently been shown that IL-27 could be a predictive
molecule of sepsis in children (153), and that the activated platelets
could be a significant source of this cytokine (154). Thrombin
formed during sepsis could lead to this release of platelet IL-27.
In addition, an increase in the level of circulating microparticles
has been reported in septic patients. These vesicles (granulocytes,
monocytes, endothelial cells, and platelets) may arise from several
cell types (22). In sepsis, the release of PMP is accompanied by an
increase of CD62P at the platelet membrane and an increase of
platelet–monocyte aggregates (31). The role of microparticles in
sepsis requires further exploration. It has been described however
that they possess strong pro-coagulant pathogenicity through the
expression of tissue factors. Some studies conducted in other con-
texts have shown that PMP are rich in CD40L (155) and IL-1 β (18,
30), which are two pro-inflammatory molecules that are strongly
associated with the pathophysiology of sepsis. It therefore becomes
important to consider PMP in the development of inflammation
during sepsis.
The role of platelets in the inflammatory phase of sepsis may not
be limited to the production of inflammatory molecules. Indeed,
in patients with uncomplicated sepsis, the level of circulating
platelet–leukocyte complexes is higher than in controls. However,
in sepsis complicated by organ failure, the number of platelet–
leukocyte complexes is decreased. This can be explained by seques-
tration of the complexes in the damaged organs, for example
the lungs (156). The same type of observation occurred in vitro,
in which strains of S. aureus isolated from bacteremia result in
aggregation, the formation of platelet–neutrophil complexes, and
activation of these neutrophils (157).
Moreover, since platelets are capable of binding to bacteria, and
even keeping them alive intracellularly, they could promote their
dissemination within the body. This mechanism was proposed in a
mouse model infected by S. pyogenes via the intraperitoneal route.
Platelet-depleted animals are unable to ensure the transport of
bacteria in the blood, lungs, and spleen, which is characterized by
a reduction in the bacterial load (through a CFU count) in these
organs after sacrifice of the animals (158).
PLATELET APOPTOSIS IN THE MICROENVIRONMENT OF SEPSIS
The involvement of platelets in sepsis is also characterized by per-
sistent thrombocytopenia in patients (159, 160). There have been
various studies done that consider thrombocytopenia a predictive
factor of the mortality rate of patients admitted to intensive care
(160, 161). Several hypotheses have been made with regard to the
decrease in circulating platelets and are presented below.
During sepsis, platelets express activation factors that promote
their sequestration in the spleen and then their destruction (162).
Platelet depletion can be accelerated if the platelet–bacteria con-
tact involves the complement system (52) or Fc-γ receptor (163).
Furthermore, sepsis is a pathological state that might promote
hemophagocytosis of platelets by macrophages which is partly
dependent on macrophage colony-stimulating factor (164).
The failure of thrombopoiesis is an unlikely hypothesis to the
degree that the plasma levels of IL-6, tumor necrosis factor (TNF)-
α, and thrombopoietin are increased in sepsis (129, 130, 165). On
the contrary, the involvement of megakaryocyte TLRs might rather
promote an overproduction of platelets.
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Another hypothesis points at sepsis-induced coagulopathy
leading to DIC, in which disseminated thrombi may immobilize
the platelets (166). The results of Tyml et al. confirmed this in a
mouse model of sepsis (132).
More recently, the scientific community has been interested
in platelet apoptosis. This mechanism of cellular death involves
an important step of nuclear transformation involving chromatin
condensation, followed by DNA fragmentation (167–169).
Apoptosis, which is known as “programed cell death,” can nor-
mally be triggered by two types of stimuli. These are referred to as
the intrinsic pathway and the extrinsic pathway.
The extrinsic pathway involves cell death receptors, such as
the apoptosis stimulating fragment (Fas) receptor, the ligands of
which are the proteins from the TNF family. The involvement
of Fas causes trimerization of the receptor, which then becomes
active, enabling it to recruit an adaptor molecule, Fas-associated
protein with death domain (FADD), which also contains a binding
domain for procaspase-8. The formation of this complex leads to
cleaving of caspase-8, which is then produced in its active dimeric
form. Caspase-8 will then either activate the sequential cascade of
the different caspases, or the previously described mitochondrial
pathway.
The intrinsic pathway is triggered following cellular stress, such
as oxidative stress. Under physiological conditions, Bcl2 protein
and other similar proteins maintain the integrity of the mito-
chondrial membrane. Under stress conditions, these proteins
are degraded. Transition pores then form on the mitochondr-
ial surface, causing them to swell and then burst. Cytochrome
C is then released in the cytoplasm and can activate the caspase
cascade (170).
In both cases, the pathways converge to activate caspase-3,
which has many substrates. The effects of caspase-3 are seen both
on the nuclear proteins involved in DNA repair and on cytoplasm
proteins such as gelsolin, which is a cytoskeletal regulator. Cleaving
of the molecules involved in cellular structure and repair causes
DNA and cytoskeletal fragmentation, but the plasma membrane
remains intact. During the formation of apoptotic bodies, a change
in the distribution of phospholipids is produced, termed “mem-
brane flip flop,” which exposes the PS on the membrane surface.
The PS constitute an “eat me” signal for the phagocytic cells, which
enables the elimination of the apoptotic bodies (170).
Platelets have also been found to possess apoptotic machinery.
The platelets express caspases 1, 3, 4, and 9. Caspases 2, 6, and
8A have a more reduced expression, and no expression for cas-
pases 5, 7, and 10 has been demonstrated. Fas are not expressed
in the platelets, but they have other cell death receptors, such
as DR3, DR5, TNF-receptor p55, and RIP. Platelets also express
proteins from the Bcl-2 family: Bcl-X, Bfl1, Bad, Bak, Bax, and
Mc1 (171).
Activation of these apoptotic molecules has been demonstrated
during storage of platelet concentrates. After 5 days of storage in
standard blood bank conditions, platelet viability decreases. This
platelet death is accompanied by an increase in PS at the cell surface
and an increase in caspase-3 activity. Caspase activation occurs in
a specific manner, since the use of an inhibitor (z-VAD-fmt) stops
this process. Platelet death is thus well associated with a specific
apoptosis (171).
This first study showed the independence of apoptosis and
platelet activation, since PS exposure was independent of the
increase in the expression of the CD63 activation marker, and
thrombin activation had no effect on caspase-3 activity. The sci-
entific community however is not in unanimous agreement. It
has even been shown that thrombin stimulation induced depo-
larization of the mitochondrial membrane, the expression of
pro-apoptotic molecules (Bax, Bak), activation of caspase-3, and
exposure of PS to the membrane (172). The action of thrombin
may not be direct and may require the release of platelet factors
that can induce apoptosis. During storage, platelets release many
soluble factors, including TNF-α, which is a strong inductor of
apoptosis through the induction of caspases.
The life span of platelets could therefore be controlled through
apoptosis. Caspase-9, for example, is required for platelet and
megakaryocyte death but is not involved in their production or
their functionality (159).
The Bcl-X family is also at the center of platelet survival. These
molecules may even determine their life span. Two missense muta-
tions of Bcl-X are capable of accelerating platelet death resulting
in severe thrombocytopenia (173).
It has also been shown that a strain of isolated E. coli in
a patient with sepsis was able to induce apoptotic manifesta-
tions of platelets, such as actin condensation, a decrease of the
mitochondrial potential, and degradation of Bcl-X. The use of
mutant and non-pathogenic strains showed that only patho-
genic strains that release toxins forming pores have the ability
to degrade Bcl-X. This applies to the alpha-toxin of E. coli and
S. aureus. These toxins probably act on calpain, since this protein
is the source of Bcl-X degradation. However, proteasome inhibi-
tion is ineffective in preventing degradation of the pro-apoptotic
protein (174). This study is the first demonstration that path-
ogenic bacteria can influence the intrinsic initiation of platelet
apoptosis. The degradation of Bcl-X suggests a new mechanism
by which bacteria may be able to cause the thrombocytope-
nia observed in patients with bacteremia. This mechanism could
then explain why depolarization of the mitochondrial membrane
potential (∆Ψm) is increased in the platelets of patients with SIRS
(175). A decrease in ∆Ψm could even be associated with SRIS
progression.
INVOLVEMENT OF PLATELETS IN SEPSIS-RELATED NETose
Another phenomenon, the formation of NETs involving platelets,
neutrophils, and bacteria, has been demonstrated and could play
an important role in sepsis. It was first described in 2004. Neu-
trophils that have been activated, particularly by IL-8, release their
granular (peptides and enzymes) and nuclear (chromatin and his-
tones) components in the microvessels where they combine to
form a network called NET (176). The use of high-resolution
electron microscopy has confirmed the structure of NET, which is
characterized by extracellular chromatin stretches that are associ-
ated with globular proteins. It has also been shown that a bacterial
environment, or that mimicked through the injection of LPS,
results in the in vivo release of NET that are able to trap bacteria
and thus reduce their spread during sepsis (177).
It was noted that bacterial trapping at NET is greater under
flow conditions, as in the blood circulation (94). NET can reach a
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diameter of 25 nm, and once combined, they form a structure that
can be over 100 nm both in diameter as well as length (94).
Aligned with DNA, NET contain the histones H1, H2A, H2B,
and H4, as well as granular proteins such as elastase, myeloper-
oxidase, and bactericidal permeability increasing protein, which
enable bacterial degradation (176). NET are able to stop both
Gram-positive and Gram-negative bacteria. The histones and BPI
have a proteolytic action on the alpha-toxin of S. aureus, as well as
on the IpaB of S. flexneri (177). C. albicans, although not a bacte-
ria, is also sensitive to NET, but its destruction may only depend
on granular proteins and not histones (177).
Neutrophil extracellular trap release occurs within 5–10 min
after stimulation of the neutrophils. This time period is too short
for the implementation of an apoptosis or necrosis mechanism.
It is therefore an active mechanism and not the consequence of
disintegration of the neutrophilic plasma membrane (176).
From a molecular viewpoint, the formation of NET involves
(178, 179):
- peptidylarginine deiminase type 4, for chromatin decondensa-
tion;
- ROS formation, which is NADPH oxidase-dependent for disin-
tegration of the nuclear membrane;
- actin cytoskeleton and microtubules for NET release.
Neutrophil extracellular trap can be released according to
three mechanisms (180): (1) a rapid mechanism (30–60 min)
involving vesicles; in this case, the neutrophils remain viable;
(2) a slower mechanism (3–4 h), resulting in rupture of the
neutrophilic plasma membrane; or (3) directly from the mito-
chondria. At present, the third mechanism and the existence of
NET composed from mitochondrial DNA remains controversial,
although one study shows that NET might be majorly composed
of mitochondrial DNA rather than nuclear DNA (181).
Lipopolysaccharide, which has traditionally been described
as a neutrophil activator, is surprisingly incapable of inducing
in vitro NET release by neutrophils. In contrast, in 2007, Clark
et al. showed in a mouse model that the intravenous injection of
LPS leads to NET formation within the first 5 min (94). A more
detailed investigation showed that LPS-induced NET formation
is not direct and requires platelet participation. Indeed, platelet
stimulation by LPS in the presence of neutrophils may not cause a
standard platelet response but might promote their adhesion; the
neutrophils would then be activated and form NET (94).
Kraemer et al. then showed that type 1 beta-defensins released
by platelets after bacterial stimulation were responsible for NET
formation (100).
Kubes presents platelets as a barometer that can detect a sub-
stantial level of bacteria. The platelets are activated by an LPS
concentration 100 times greater than that inducing neutrophil
activation. The platelets may therefore come to the assistance of
the neutrophils by enabling them to form NET when the bacterial
load is too high and their normal functions are insufficient for
correctly eliminating the bacteria (177). NET could be the innate
“last chance” defense.
Neutrophil extracellular traps have been shown to have a pos-
itive impact on the destruction of pathogens during bacteremia.
Conversely, they may alter the microvascular circulation by pro-
moting the formation of microthrombi, thereby also preventing
the immune cells from reaching the bacteria. In addition, their
components may have a toxic effect on the host cells. This was con-
firmed in vitro on human umbilical vein endothelial cell (HUVEC)
(94). Hepatotoxicity has been observed in vivo following the
release of NET, which was measured by the release of alanine
aminotransferase and an occlusion of the liver sinusoids (94).
The histones released in the extracellular medium possess pro-
thrombotic activity and are capable of activating the platelets via
their TLR-2 and -4 (90). This phenomenon may be extrapolated
to the NET histones. In this case, NET would be responsible for
platelet overactivation, which may lead to thrombi formation. The
potential detrimental effect of NET is another illustration of the
alteration of platelet function during sepsis.
CONCLUSION
The implication of platelets in the inflammatory response marks
a veritable turning point in the understanding of platelet physi-
ology and opens new fields of investigation that have been up to
now somewhat neglected. The identification of platelets in the var-
ious inflammatory mechanisms places them at the center of innate
immunity, whether in the recognition of pathogens, signal trans-
duction, or the release of cytokines/chemokines. This functional
similarity with leukocytes shows that both of these cells types are
not so different.
Anucleated platelets are only found in mammals. In the lower
vertebrates, such as birds, reptiles, amphibians, or fish, hemostatic
function is ensured by nucleated thrombocytes. With regard to
invertebrate species, they do not possess platelets per se, but the
hemolymph contains a type of nucleated cell called a hemocyte
that expresses TLR, which is capable of phagocytizing the foreign
body or secreting antimicrobial proteins. It is this same cell how-
ever that regulates coagulation and healing. By compiling all of
these characteristics, it is possible to discuss a possible common
evolution between platelets and leukocytes, followed by a dissoci-
ation, proportional to the evolution of the species (1, 3, 4, 182),
despite this is debated.
All of the studies presented in this thesis generally show that
platelets are able to cover the majority of the steps of inflammation
and thus confirm their total involvement in the orchestration of
this pathophysiological state. By modulating both the acute effec-
tor phase of inflammation and the maintenance of this process,
platelets may become a therapeutic target.
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